Responding to the publication of Dr Brian Montgomery's Review of Access to New Medicines this morning, ABPI Director - Scotland, Sandra Auld, said: “I am pleased that the review has now been published. Throughout, Dr Montgomery has focused on what is best for patients, a focus we endorse.
14 Dec 2016 Posted in ABPI statement By Press Office
"His review's comments on the need for earlier collaboration between NHSScotland and the pharmaceutical industry in bringing new medicines to market, are very welcome and will be important in reducing delays for patients gaining access to new medicines. We look forward to working with NHSScotland on how this early engagement can be introduced to the process.
"Similarly, the recommendation that we need an alternative assessment pathway for ultra-orphan medicines is one that we feel could make a real difference to patients accessing these medicines.
"The entire review by Dr Montgomery has been run in an open and consultative manner, and as the body representing the pharmaceutical industry to the review, we are committed to working together with everyone involved to iron out the details and the practicalities of Dr Montgomery's recommendations and I look forward to ABPI Scotland's involvement in the multi-agency taskforce."
ABPI Press Office
Telephone during work hours (9am to 5pm Monday to Friday): +44 (0) 20 7747 7147 or +44 (0) 20 7747 1441
Telephone out of hours (5pm to 9am and weekends): +44 (0) 20 7747 1445
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.